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(74.5  7 years, 46.4% male) without dementia collected salivary cortisol
after awakening and late in the evening. After 4 years, 852 persons
received follow-up. At baseline and follow-up, global cognitive function-
ing, verbal memory performance, and processing speed were assessed
using the MMSE; the 15 Word Learning Test (verbal learning during 3
trials, delayed recall, and memory retention (%)); and a digit-coding task
(score range 0-50). Using linear mixed models adjusted for age, gender,
education, smoking, alcohol use, BMI, hypertension, diabetes, vascular
disease, and depressive symptoms, the cross-sectional and longitudinal
associations of awakening and evening cortisol and diurnal variability (per
nmol/l increase) with cognitive outcomes were estimated. Results: Cross-
sectionally, higher evening cortisol levels were associated with poorer
delayed recall (B  -0.05; 95% CI -0.09 to -0.01) and poorer memory
retention (B  -0.42; 95% CI -0.70 to -0.14), but not with verbal learning.
High diurnal variability of cortisol was related to better scores on verbal
learning (B  0.13; 95% CI 0.02 to 0.24); better delayed recall (B  0.08;
95% CI 0.02 to 0.14); and better memory retention (B  0.59; 95% CI 0.13
to 1.04). No associations were found between salivary cortisol and MMSE
or processing speed. Also, awakening levels were not associated with any
of the cognition measures. Although all cognitive scores declined over
time, no longitudinal associations were observed between any of the
cortisol measures and cognitive decline for any cognitive test. Conclu-
sions: In this older non-demented population, higher levels of evening
cortisol and low diurnal variability of cortisol are associated with poorer
verbal memory performance, but not with memory decline or decline in
other cognitive domains after 4 years of follow-up. Our findings do not
support the hypothesis that excessive glucocorticoids increase the risk for
Alzheimer’s disease.
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Background: Evidence for an association between statins and dementia is
mixed. This study aims to examine the association between statin use and
incidence of dementia and cognitive impairment without dementia over 7
years of follow-up. Methods: The Sacramento Area Latino Study on
Aging (SALSA- AG12975) is a population-based cohort study of 1,789
Mexican-Americans aged 60-101 done from 1998-2008. Participants had
interviews and cognitive evaluations performed every 12 to 15 months.
Those who fell below the 20th percentile on at least one of two cognitive
tests (Modified Minimental State Exam or delayed word list recall) were
evaluated clinically. Diagnosis of dementia or cognitive impairment with-
out dementia (CIND) was finalized by an expert adjudication team. A total
of 1674 participants without dementia/CIND at baseline were included in
these analyses. Dementia/CIND were combined to increase statistical
power. Statin use was verified at a participant’s home visit by medicine
cabinet inspection and classified using a CDC standardized system. LDL-C
was obtained from a fasting blood sample. Cox proportional hazards
models were used to evaluate the association between statin use over time
and combined incidence of dementia/CIND. Results: Overall, 452 of 1674
participants (27%) took statins at any time during the study. The most
commonly used statins on average over time were: Atorvastatin (46%),
lovastatin (29%), pravastatin (26%), and simvastatin (22%). Statin use was
associated with a greater decline in LDL-C over the follow up period (-22
vs. -7.8 ug/dl, p.0001). In all, 152 participants developed dementia/
CIND. Statin users experienced lower rates of dementia/CIND than non-
users (HR0.52, 95% CI: 0.34,0.80) in proportional hazards regression
models adjusted for education, smoking status, APOE 4, and baseline
stroke or diabetes. LDL-C was associated with a lower risk of dementia/
CIND (HR for interquartile range of 45 ug/dl: 0.70,p0.003); effect
modification of this association by statin use was not significant (p0.33).
LDL-C adjustment reduced the statin-dementia association by 26%. Con-
clusions: Statins are linked to lower risks of cognitive impairment and
lower LDL-C may be a partial mediator of this association. However,
LDL-C is associated with cognitive impairment after adjustment for statin.
Statins may influence neurodegeneration through non lipid pathways.
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Background: An emerging body of evidence suggests that cardiovascular-
risk factors may contribute to Alzheimer’s disease pathophysiology and
clinical symptoms. Metabolic Syndrome (MS) is a rapidly growing major
public health concern characterized by insulin resistance (IR), and studies
have clearly linked it with cardiovascular risk and the future development
of diabetes. Numerous studies have demonstrated that diabetes is a strong
risk factor for cognitive decline and dementia. More recently, MS has been
directly associated with cognitive decline. Methods: This lecture will
review and discuss the association between metabolic syndrome and Alz-
heimer’s disease and the implication of lifestyle and exercise interventions
on metabolic syndrome individuals who at risk for developing Azheimer’s
disease. Results: The results of an evidence-based and systematic review
approach will be presented. Conclusions: 1) to examine current evidence
on the effects of metabolic syndrome, lifestyle, and physical activity on AD
and related cognitive impairments, 2) to review common clinical issues
related to detect early cognitive impairment on metabolic syndrome , 3) to
make recommendations for current practice based on evidence from the
literature.
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Background: Subjects with mild cognitive impairment (MCI) are at
heightened risk of conversion to dementia. Using longitudinal information
on changes in risk factors has the potential to substantially improve our
ability to identify subjects at greatest risk of conversion. However, limited
statistical methods are available for modeling multi-state disease processes
in which the rate of transition between disease states is age-dependent and
exact time of transition between states may be unknown, both of which are
issues in studies of Alzheimer’s disease. Methods: We have developed a
new statistical model for estimating the effect of risk factors on conversion
from normal cognition to MCI and dementia. This model makes use of a
Markov process to characterize risk factors for transition between multiple
disease states. We applied this model to the National Alzheimer’s Coor-
dinating Center’s Uniform Data Set, a longitudinal study of subjects eval-
uated at one of the National Institute on Aging’s Alzheimer’s Disease
Centers. We used our model to estimate risk of progression to amnestic
MCI and dementia for 2724 subjects who had at least two observations.
Risk factors considered in our model were years of education, history of
dementia in a first degree relative, and MCI affecting additional domains
beyond memory. Results: Our model indicated strong age-dependent
trends in rates of conversion between all disease states. We additionally
found that subjects with a history of dementia in a first degree relative were
significantly more likely to transition from normal cognition to MCI
(hazard ratio: 1.918, 95% CI: (1.02, 3.60)) after adjusting for education and
multi-domain MCI. Conclusions: Our model confirms some previously
identified risk factors for conversion to MCI and illustrates the way in
which multi-state models can be used to identify risk factors for conver-
sion. This type of statistical model is necessary to appropriately account for
features of the Alzheimer’s disease process including age-related changes
in conversion rates and imprecisely observed times of transition between
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